JPH08508169A - 遺伝子の転写の抑制方法 - Google Patents
遺伝子の転写の抑制方法Info
- Publication number
- JPH08508169A JPH08508169A JP6521676A JP52167694A JPH08508169A JP H08508169 A JPH08508169 A JP H08508169A JP 6521676 A JP6521676 A JP 6521676A JP 52167694 A JP52167694 A JP 52167694A JP H08508169 A JPH08508169 A JP H08508169A
- Authority
- JP
- Japan
- Prior art keywords
- ikb
- cells
- activation
- cell
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.NF-KBの活性を抑制することにより高等真核生物細胞中の遺伝子の転写を抑 制する方法であって、細胞をIkB-αのタンパク質分解を特異的に抑制する物質で 処理することを特徴とする高等真核生物細胞中の遺伝子の転写の抑制方法。 2.a)IkB-αを含む基質を、試験物質の存在下で、IkB-αに対しタンパク質分 解活性を示す製剤で処理し、そして試験物質がIkB-αのタンパク質分解を特異的 に抑制するか否か、またどの程度なのかを測定し、必要により b)試験物質の存在下で、NF-KB活性化に応答してリポーター遺伝子構築物で形 質転換された高等真核生物細胞、特に、ヒト細胞中でNF-KB活性化を誘発し、そ してリポーター遺伝子の発現を測定することにより、 試験物質をIkB-αのタンパク質分解を特異的に抑制するそれらの能力につき試 験することを特徴とするNF-KB活性化を抑制する物質の同定方法。 3.無細胞系を工程a)で使用することを特徴とする請求の範囲第2項に記載の 方法。 4.固定担体に結合された組換えIkB-αを工程a)でIkB-αを含む基質として使 用することを特徴とする請求の範囲第3項に記載の方法。 5.溶液中の組換えIkB-αを工程a)でIkB-αを含む基質として使用することを 特徴とする請求の範囲第3項に記載の方法。 6.ホスホリル化IkB-αを工程a)でIkB-αを含む基質として使用することを特 徴とする請求の範囲第3項に記載の方法。 7.ホスホリル化IkB-αを使用し、これがNF-KB活性化を誘導する物質による細 胞の処理そしてIkB-αのタンパク質分解を抑制し、IkB-αのホスホリル化形態の 蓄積に影響する物質による細胞の処理から得られたことを特徴とする請求の範囲 第6項に記載の方法。 8.IkB-αに対しタンパク質分解活性を示す製剤につき、細胞の抽出物を使用し 、これらの細胞がNF-KB活性化のインデューサーまたはこのような抽出物のフラ クションで処理されたことを特徴とする請求の範囲第2項に記載の方法。 9.工程a)において無細胞系中で、組換えIkB-αを基質として使用し、そして 工 程b)において、NF-KB活性化に応答してルシフェラーゼ遺伝子構築物で形質転換 され、そしてNF-KB活性化のインデューサーで刺激されたヒト細胞を試験物質で 処理し、そしてルシフェラーゼ発現を測定することを特徴とする請求の範囲第2 項に記載の方法。 10.ルシフェラーゼ遺伝子構築物が少なくとも2種のKBモチーフを含むことを特 徴とする請求の範囲第9項に記載の方法。 11.転写因子NF-KBにより調節される遺伝子の発現を伴う病状の治療のためにIkB -αのタンパク質分解を特異的に抑制する物質。 12.IkB-αのタンパク質分解を特異的に抑制する一種以上の物質を活性成分とし て含む医薬。 13.転写因子NF-KBにより調節される遺伝子の発現を伴う病状の治療のための医 薬の製造のためのIkB-αのタンパク質分解を特異的に抑制する物質の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4311835A DE4311835A1 (de) | 1993-04-07 | 1993-04-07 | Verfahren zur Inhibierung der Transkription von Genen |
| DE4311835.6 | 1993-04-07 | ||
| PCT/EP1994/001014 WO1994023045A1 (de) | 1993-04-07 | 1994-03-31 | Verfahren zur inhibierung der transkription von genen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08508169A true JPH08508169A (ja) | 1996-09-03 |
| JP3970921B2 JP3970921B2 (ja) | 2007-09-05 |
Family
ID=6485229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52167694A Expired - Lifetime JP3970921B2 (ja) | 1993-04-07 | 1994-03-31 | 遺伝子の転写の抑制方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6090542A (ja) |
| EP (1) | EP0693129B1 (ja) |
| JP (1) | JP3970921B2 (ja) |
| AT (1) | ATE331799T1 (ja) |
| AU (1) | AU691492B2 (ja) |
| DE (2) | DE4311835A1 (ja) |
| ES (1) | ES2268685T3 (ja) |
| WO (1) | WO1994023045A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| GB9424497D0 (en) * | 1994-12-05 | 1995-01-25 | Karobio Ab | Reporter cell line |
| US5597898A (en) * | 1995-02-15 | 1997-01-28 | Yale University | NF-κB activation regulatory protein, IκB-β |
| IT1293069B1 (it) * | 1997-07-01 | 1999-02-11 | Consiglio Nazionale Ricerche | Inibitori di nf-kb come attivatori di hsf e induttori di proteine da shock termico |
| IT1289250B1 (it) | 1996-12-13 | 1998-09-29 | Consiglio Nazionale Ricerche | Impiego di 2 ciclopenten 1-one e suoi derivati come inibitori del fattore nf-kb |
| WO1998022577A1 (en) * | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
| US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
| DE60014987T2 (de) * | 1999-02-22 | 2005-11-10 | Matsushita Electric Industrial Co., Ltd., Kadoma | Verfahren zum Nachweis von Bakterien |
| JP2004537506A (ja) | 2001-03-01 | 2004-12-16 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 血液細胞欠乏症を治療するためのある種のステロイドの使用 |
| WO2003048202A2 (en) * | 2001-12-03 | 2003-06-12 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68910682T2 (de) * | 1988-03-01 | 1994-06-01 | Whitehead Biomedical Inst | Aktivierung der nf-kappa b-vorstufe. |
| CA1340588C (en) * | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
| US5164388A (en) * | 1988-10-19 | 1992-11-17 | Abbott Laboratories | Heterocyclic peptide renin inhibitors |
| JP2701932B2 (ja) * | 1989-04-10 | 1998-01-21 | サントリー株式会社 | タンパク質分解酵素阻害剤 |
| KR100194562B1 (ko) * | 1989-07-18 | 1999-06-15 | 로버트 반 노스트랜드 | 전사단계에서의 유전자 발현의 조절방법 및 유전자 발현 조절 인자로서 작용할수 있는 화학물의 발견방법 |
| US5254682A (en) * | 1989-12-08 | 1993-10-19 | Merck & Co., Inc. | Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs |
| US5192668A (en) * | 1990-10-11 | 1993-03-09 | Merck & Co., Inc. | Synthesis of protease inhibitor |
| WO1992014696A2 (en) * | 1991-02-22 | 1992-09-03 | The Du Pont Merck Pharmaceutical Company | SUBSTITUTED α-AMINOALDEHYDES AND DERIVATIVES |
| EP0584238A1 (en) * | 1991-05-17 | 1994-03-02 | Chiron Corporation | INHIBITOR OF NF-$g(k)B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF |
-
1993
- 1993-04-07 DE DE4311835A patent/DE4311835A1/de not_active Ceased
-
1994
- 1994-03-31 ES ES94913099T patent/ES2268685T3/es not_active Expired - Lifetime
- 1994-03-31 AU AU65380/94A patent/AU691492B2/en not_active Expired
- 1994-03-31 DE DE59410439T patent/DE59410439D1/de not_active Expired - Lifetime
- 1994-03-31 AT AT94913099T patent/ATE331799T1/de active
- 1994-03-31 US US08/530,358 patent/US6090542A/en not_active Expired - Lifetime
- 1994-03-31 JP JP52167694A patent/JP3970921B2/ja not_active Expired - Lifetime
- 1994-03-31 EP EP94913099A patent/EP0693129B1/de not_active Expired - Lifetime
- 1994-03-31 WO PCT/EP1994/001014 patent/WO1994023045A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ATE331799T1 (de) | 2006-07-15 |
| AU691492B2 (en) | 1998-05-21 |
| EP0693129A1 (de) | 1996-01-24 |
| AU6538094A (en) | 1994-10-24 |
| EP0693129B1 (de) | 2006-06-28 |
| WO1994023045A1 (de) | 1994-10-13 |
| US6090542A (en) | 2000-07-18 |
| JP3970921B2 (ja) | 2007-09-05 |
| DE59410439D1 (de) | 2006-08-10 |
| ES2268685T3 (es) | 2007-03-16 |
| DE4311835A1 (de) | 1994-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ciechanover et al. | The ubiquitin‐mediated proteolytic pathway and mechanisms of energy‐dependent intracellular protein degradation | |
| Sekito et al. | RTG-dependent mitochondria-to-nucleus signaling is regulated by MKS1 and is linked to formation of yeast prion [URE3] | |
| Lee et al. | Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1 | |
| Deiss et al. | A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal | |
| Li et al. | RNase-l-dependent destabilization of interferon-induced mRNAs: a role for the 2–5A system in attenuation of the interferon response | |
| Rhoads et al. | Mechanism of action and regulation of protein synthesis initiation factor 4E: effects on mRNA discrimination, cellular growth rate, and oncogenesis | |
| Taylor et al. | Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain | |
| AU2027592A (en) | Atp-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting | |
| FOLCO et al. | Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin–proteasome pathway | |
| JPH04506298A (ja) | 生きている細胞の中のn末端の法則の経路の抑制 | |
| JP3970921B2 (ja) | 遺伝子の転写の抑制方法 | |
| Freeman et al. | Effects of the v-mos oncogene on Xenopus development: meiotic induction in oocytes and mitotic arrest in cleaving embryos. | |
| Heckt et al. | Parathyroid hormone induces expression and proteolytic processing of Rankl in primary murine osteoblasts | |
| Tao et al. | The NIT2 nitrogen regulatory protein of Neurospora: expression and stability of nit-2 mRNA and protein | |
| SCHIMKE | Protein Turnover and the Regulation of | |
| Cohrs et al. | Occurrence of 2-5A and RNA degradation in the chick oviduct during rapid estrogen withdrawal | |
| Nahreini et al. | Proteasome activity is critical for the cAMP-induced differentiation of neuroblastoma cells | |
| JPH07170998A (ja) | NF−κBの調節方法 | |
| Porro et al. | The erythrocyte skeletons of β‐adducin deficient mice have altered levels of tropomyosin, tropomodulin and EcapZ | |
| Chen et al. | Ubiquitylation and destruction of endogenous c-mycS by the proteasome: are myc boxes dispensable? | |
| CA2159822C (en) | Process for inhibiting the transcription of genes | |
| AU732547B2 (en) | Novel cyclin-selective ubiquitin carrier polypeptides | |
| Ponta et al. | The Sex‐Factor‐Dependent Exclusion of Coli Virus T7 | |
| JPH10191977A (ja) | チオレドキシン改変体及び該改変体を含むap−1の転写活性能を増強する因子 | |
| Sreevalsan et al. | Inhibition by puromycin of the initiation of synthesis of infectious RNA and virus by chicken embryo cells infected with western equine encephalomyelitis virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031106 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20031224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040623 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070607 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100615 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110615 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110615 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120615 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130615 Year of fee payment: 6 |
|
| EXPY | Cancellation because of completion of term |